Two Sigma Investments, LP Graphite Bio, Inc. Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.24 - $2.66 $86,562 - $102,793	-38,644 Reduced 22.77%	131,068 $343,000
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $3,723 - $4,731	1,708 Added 1.02%	169,712 $420,000
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $60,040 - $82,161	24,308 Added 16.92%	168,004 $436,000
Q1 2023 May 15, 2023	SELL	$1.85 - $3.21 $119,641 - $207,593	-64,671 Reduced 31.04%	143,696 $352,000
Q4 2022 Feb 14, 2023	SELL	$2.82 - $3.59 $146,530 - $186,539	-51,961 Reduced 19.96%	208,367 $691,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $498,962 - $750,212	-176,937 Reduced 40.46%	260,328 $825,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $935,747 - $2.29 Million	437,265 New	437,265 $1.2 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.